PROTEIN DEGRADERS AND USES THEREOF
Summary
The European Patent Office published Kymera Therapeutics' patent application EP4499149A1 for protein degrader compounds and their therapeutic uses. The patent covers chemical compositions under IPC classifications C07D 401/14, C07D 409/04, C07D 487/04 and their applications in treating diseases. This is a standard patent publication granting exclusive rights across 39 designated European member states.
What changed
Kymera Therapeutics, Inc. received European Patent EP4499149A1 for protein degrader compounds and methods of use, published March 25, 2026. The patent application covers specific chemical compounds (IPC: A61K 47/55, A61K 31/4545, C07D 401/14, C07D 409/04, C07D 487/04) and their therapeutic applications. The designated states include all EU member states plus Switzerland, Norway, and other European Economic Area countries.\n\nPharmaceutical companies and researchers developing targeted protein degradation therapeutics should conduct freedom-to-operate analyses before advancing similar programs in Europe. Competitors should evaluate whether licensing negotiations with Kymera are necessary for compounds falling within the patent scope. The patent term is 20 years from filing date with potential supplementary protection certificates for pharmaceutical applications.
What to do next
- Conduct freedom-to-operate analysis for any protein degrader programs targeting European markets
- Evaluate whether licensing from Kymera Therapeutics is required for overlapping compound claims
- Review patent family status in other jurisdictions (US, PCT) for global coverage
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PROTEIN DEGRADERS AND USES THEREOF
Publication EP4499149A1 Kind: A1 Mar 25, 2026
Applicants
Kymera Therapeutics, Inc.
Inventors
YANG, Bin, ZHENG, Xiaozhang, SINTCHAK, Michael D., WEISS, Matthew M., YATES, Christopher M., ZHANG, Yi, ZHU, Xiao, PENNINGTON, Lewis Dale, JI, Nan
IPC Classifications
A61K 47/55 20170101AFI20260217BHEP A61K 31/4545 20060101ALI20260217BHEP C07D 401/14 20060101ALI20260217BHEP C07D 409/04 20060101ALI20260217BHEP C07D 487/04 20060101ALI20260217BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for ChangeBridge: EPO Bulletin - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Organic Chemistry (C07D) publishes new changes.